BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
UBS
Cipla
Moodys
Express Scripts
Citi
Harvard Business School
Colorcon
Merck
Accenture

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,320,970

« Back to Dashboard

Which drugs does patent 7,320,970 protect, and when does it expire?

Patent 7,320,970 protects PREFEST and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 7,320,970
Title:Low dose estrogen interrupted hormone replacement therapy
Abstract:A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g per day of norgestimate.
Inventor(s): Casper; Robert F. (Toronto, CA), Shangold; Gary A. (Califon, NJ), Ausmanas; Militza K. (Lake Forest, IL)
Assignee: Duramed Pharmaceutials, Inc. (Cincinnati, OH) Jencap Research Ltd. (Toronto, Ontario, CA)
Application Number:11/439,171
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery; Device;

Drugs Protected by US Patent 7,320,970

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Womens PREFEST estradiol; norgestimate TABLET;ORAL 021040-001 Oct 22, 1999 DISCN Yes No ➤ Subscribe ➤ Subscribe Y PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,320,970

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,747,019 Low dose estrogen interrupted hormone replacement therapy ➤ Subscribe
7,078,394 Low dose estrogen interrupted hormone replacement therapy ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,320,970

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200102860 ➤ Subscribe
Russian Federation 2245713 ➤ Subscribe
Poland 202043 ➤ Subscribe
Poland 350854 ➤ Subscribe
New Zealand 514463 ➤ Subscribe
Mexico PA01009813 ➤ Subscribe
Japan 2002541126 ➤ Subscribe
Hungary 0200416 ➤ Subscribe
European Patent Office 1165183 ➤ Subscribe
Czech Republic 20013493 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Farmers Insurance
Citi
Colorcon
Chinese Patent Office
Dow
Moodys
US Army
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot